Regulatory Affairs in Pharma
                     Regulatory Affairs in Pharma
Navigating the Path from Innovation to Patient Access
What Is Regulatory Affairs?
Strategic Integrator Core Mission
RA owns a company's relationship with Ensure medicines are developed, 
drug and biologic regulators — from the manufactured, approved, and maintained 
first pre-IND meeting through marketing in line with applicable laws and regulatory 
approval and every post-market change. expectations — bridging science, 
compliance, and business strategy across 
the entire product lifecycle.
The RA Function Across Product Lifecycle
Pre-clinical & Approval
IND NDA/BLA/510(k) 
Regulatory strategy preparation and 
and filings submission
Clinical Trials Post-Approval
Protocol oversight Labeling, PV, and 
and safety reporting change control
Regulatory Affairs acts as the strategic backbone at every stage — from first-in-human studies to long-term market stewardship.
Medical Device Regulatory Pathway
Quality & Global Standards
• ISO 13485 and design controls replace pharmaceutical GMP batch records
• ISO 14971 anchors risk management throughout device development
• EU MDR/IVDR via Notified Bodies for CE mark — raised evidence 
requirements significantly
FDA Submission Pathways
NDA BLA
New Drug Application Biologics License Application
Small-molecule drugs. Includes full Biologics, vaccines, and gene therapies 
chemistry, manufacturing, and clinical with additional manufacturing controls 
data package. and characterization.
ANDA
Abbreviated NDA
Generic drugs leveraging reference product data; bioequivalence replaces full clinical 
trials.
Global Regulatory Agencies
FDA — USA EMA — Europe PMDA & CDSCO
Gold standard globally; Centralized procedure for Japan and India regional 
approval often required EU-wide approval; stricter authorities operating 
for entry into other pharmacovigilance within harmonized ICH 
markets worldwide. reporting requirements. guidelines.
ICH & CTD: International harmonization via the Common Technical Document reduces submission duplication across jurisdictions.
Post-Approval Compliance & Pharmacovigilance
Annual Reports & SupplementAsdverse Event Monitoring REMS Programs
CBE (Changes Being Effected) and PAS Continuous safety surveillance with Risk Risk Evaluation and Mitigation 
(Prior Approval Supplement) Management Plans (RMP) ensure Strategies impose structured safeguards 
submissions track all post-market ongoing benefit-risk assessment for high-risk products to protect patients 
product modifications. throughout product life. at scale.
Key RA Responsibilities & Skills
1 Strategic Planning 2 Submission Management
Determine filing strategy, timing, and Prepare comprehensive dossiers and 
data requirements across all global respond to health authority questions 
regions. with accuracy and speed.
3 Stakeholder Liaison
Lead FDA meetings, manage health authority interactions, and coordinate cross-functional 
teams.
The Future of Regulatory Affairs
Digital Transformation
AI-driven documentation, real-world evidence integration, and digital health 
submissions reshape the submission landscape.
Emerging Modalities
Cell and gene therapies, personalized medicine, and AI/ML-based products demand 
adaptive regulatory frameworks.
Accelerated Pathways
Breakthrough Designation, Fast Track, and Priority Review compress development 
timelines for critical therapies.
Sources
• Regulatory Affairs in the Pharmaceutical Industry
• Regulatory Affairs Services in Medical Devices